Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF

被引:33
|
作者
Funaoka, K
Shindoh, M
Yoshida, K
Hanzawa, M
Hida, K
Nishikata, S
Totsuka, Y
Fujinaga, K
机构
[1] HOKKAIDO UNIV, SCH DENT, DEPT ORAL PATHOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN
[2] HOKKAIDO UNIV, SCH DENT, DEPT ORAL SURG 2, SAPPORO, HOKKAIDO 060, JAPAN
[3] SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOL MOL, SAPPORO, HOKKAIDO 060, JAPAN
关键词
D O I
10.1006/bbrc.1997.6909
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
p21(Waf1/Cip1) is one of the key regulatory proteins in cell cycle, terminal differentiation, and apoptosis. Its promoter was shown to be transactivated by the wild-type p53 protein as well as in a p53-independent manner. In this report, we demonstrate that E1AF, an ets-related transcription factor, activated the human p21(Waf1/Cip1) promoter by interacting with the ets-binding sites located close to the two previously identified p53-responsive elements. Northern blot analysis revealed that p21(Waf1/Cip1) and E1AF were correlatively upregulated in response to cisplatin treatment in SiHa cells. Transient expression assays demonstrated that E1AF can activate the p21(Waf1/Cip1) promoter-driven luciferase reporter gene in SiHa cells. The p21(Waf1/Cip1) promoter activity was also increased in p53-null Saos2 osteosarcoma cells, but was markedly reduced when the ets-binding sites were deleted. These results indicate that E1AF positively regulates transcription from the p21(Waf1/Cip1) promoter in response to genotoxic stresses. (C) 1997 Academic Press.
引用
收藏
页码:79 / 82
页数:4
相关论文
共 50 条
  • [21] p21 (WAF1/CIP1) is required for the mitogenic response to intestinal resection
    Stern, LE
    Falcone, RA
    Kemp, CJ
    Erwin, CR
    Warner, BW
    JOURNAL OF SURGICAL RESEARCH, 2000, 90 (01) : 45 - 50
  • [22] Polymorphism of the p21 (WAF1/CIP1) gene in primary gastric cancer
    Kim, YJ
    Kim, HR
    Kim, DY
    Soh, BJ
    Kim, HJ
    Kim, SK
    Kim, KG
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 683 - 687
  • [23] P21 Waf1/Cip1 as a therapeutic target in breast and other cancers
    Weiss, RH
    CANCER CELL, 2003, 4 (06) : 425 - 429
  • [24] p21(WAF1/CIP1) and terminal differentiation control of normal epithelia
    Missero, C
    Dotto, GP
    MOLECULAR AND CELLULAR DIFFERENTIATION, 1996, 4 (01): : 1 - 16
  • [25] Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma
    Ohata, Masahiko
    Nakamura, Shinobu
    Fujita, Hiroyuki
    Isemura, Mamoru
    BIOMEDICAL RESEARCH-TOKYO, 2005, 26 (03): : 91 - 98
  • [26] The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis
    Gartel, AL
    LEUKEMIA RESEARCH, 2005, 29 (11) : 1237 - 1238
  • [27] Proteasome-dependent regulation of p21(WAF1/CIP1) expression
    Blagosklonny, MV
    Wu, GS
    Omura, S
    ElDeiry, WS
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 227 (02) : 564 - 569
  • [28] P21 (WAF1/CIP1) can inhibit cardiac myocyte apoptosis
    Wang, J
    Cakulev, IT
    Abdellatif, M
    Schneider, MD
    CIRCULATION, 2000, 102 (18) : 168 - 169
  • [29] Characterization of a panel of novel anti-p21(Waf1/Cip1) monoclonal antibodies and immunochemical analysis of p21(Waf1/Cip1) expression in normal human tissues
    Fredersdorf, S
    Milne, AW
    Hall, PA
    Lu, X
    AMERICAN JOURNAL OF PATHOLOGY, 1996, 148 (03): : 825 - 835
  • [30] Regulation of p21(WAF1/CIP1) by interferon regulatory factor-1 in hepatocellular carcinomas.
    Koh, N
    Tamori, A
    Nishiguchi, S
    Moriyama, Y
    Fujimoto, S
    Seki, S
    Otani, S
    Kinoshita, H
    Kuroki, T
    HEPATOLOGY, 1997, 26 (04) : 1652 - 1652